Results 91 to 100 of about 13,707 (310)

Mepolizumab and benralizumab in patients with severe asthma and a history of eosinophilic granulomatosis with polyangiitis

Frontiers in Medicine
Introduction Asthma associated with eosinophilic granulomatosis with polyangiitis (EGPA) is often severe and corticosteroid-dependent, leading to significant morbidity.
C. Desaintjean, K. Ahmad, J. Traclet, Mathieu Gerfaud-Valentin, C. Durel, J. Glérant, Arnaud Hot, F. Lestelle, Sabine Mainbourg, M. Nasser, P. Sève, S. Turquier, Gilles Devouassoux, V. Cottin   +13 more
semanticscholar   +1 more source

Sustained efficacy of mepolizumab in patients with severe chronic rhinosinusitis with nasal polyps: SYNAPSE 24‐week treatment‐free follow‐up

International Forum of Allergy and Rhinology, 2023
In the 52‐week Phase III SYNAPSE study, mepolizumab given every 4 weeks (100 mg subcutaneously) reduced nasal polyp (NP) size, improved symptoms and quality of life (QoL), and reduced corticosteroid use and number of sinus surgeries in patients with ...
M. Desrosiers, Z. Diamant, P. Castelnuovo, P. Hellings, Joseph K. Han, A. Peters, J. Silver, Steven G. Smith, A. Fuller, Ana R. Sousa, R. Chan, P. Gevaert   +11 more
semanticscholar   +1 more source

Impact of baseline clinical asthma characteristics on the response to mepolizumab: a post hoc meta-analysis of two Phase III trials

Respiratory Research, 2021
Background Severe asthma is associated with a broad range of phenotypes and clinical characteristics. This analysis assessed whether select baseline patient characteristics could prognosticate mepolizumab efficacy in severe eosinophilic asthma.
Catherine Lemiere, Camille Taillé, Jason Kihyuk Lee, Steven G. Smith, Stephen Mallett, Frank C. Albers, Eric S. Bradford, Steven W. Yancey, Mark C. Liu   +8 more
doaj   +1 more source

Stratification of eosinophilic asthma patients treated with reslizumab and GINA Step 4 or 5 therapy [PDF]

, 2017
Reslizumab, an anti-interleukin-5 monoclonal antibody, significantly reduces exacerbation frequency and improves lung function, asthma control and quality of life in adults with severe eosinophilic asthma, as demonstrated in Phase III studies.
Brusselle, Guy, Buhl, Roland, Canvin, Janice, Sun, Shawn X, Weiss, Sivan   +4 more
core   +3 more sources

The Dental Status of Patients Taking Common Biologic Agents: A Single‐Center Cross‐Sectional Study

Oral Diseases, EarlyView.
ABSTRACT Objectives Despite expanding use and medical applications, little is known about the impact of biologic agents (BAs) on dental treatment. The aim of this study was to investigate the dental status of patients on common classes of BAs to understand treatment needs and use in this population.
Shivani Shah, Nila Veerabagu, Nana A. A. Essel, Neda Mahjour, Katherine France   +4 more
wiley   +1 more source

Distinct trajectories of treatment response to mepolizumab toward remission in patients with severe eosinophilic asthma

European Respiratory Journal
Graphical abstract Overview of the study. OCS: oral corticosteroid; ACQ-5: Asthma Control Questionnaire (5-item); FEV1: forced expiratory volume in 1 s. Background Patients with severe eosinophilic asthma, characterised by a high disease burden, benefit ...
Yuto Hamada, Dennis Thomas, E. Harvey, S. Stevens, M. Fricker, H. Lewthwaite, Vanessa M McDonald, Andrew Gillman, M. Hew, V. Kritikos, J.W. Upham, P. Gibson   +11 more
semanticscholar   +1 more source

Eosinophils depletion therapy for severe asthma management following favorable response to mepolizumab

Respiratory Medicine Case Reports, 2019
We described three severe asthmatics whose asthma symptoms were rapidly improved by benralizumab following favorable response to mepolizumab. Benralizumab-induced eosinophil depletion contributed to clinical improvement of severe asthma after mepolizumab-
Osamu Matsuno, Seijiro Minamoto
doaj  

New and developing non-adrenoreceptor small molecule drugs for the treatment of asthma [PDF]

, 2017
Introduction: Inhaled corticosteroids (ICS) alone or in combination with an inhaled long-acting beta2-agonist (LABA) are the preferred long-term treatment for adults and adolescents with symptomatic asthma.
Thomson, Neil C.
core   +1 more source

Contemporary Concise Review 2024: Chronic Obstructive Pulmonary Disease

Respirology, EarlyView.
SUMMARY OF KEY POINTS Non‐smoking COPD is common in LMICs, especially in women. Biomass fuel and air pollution are major risk factors with distinct pathophysiology. The ‘eosinophilic’ endotype in COPD is biologically distinct from asthma. PRISm, FEV1/FVC Z‐scores, and quantitative CT improve early COPD detection.
Sarita Thawanaphong, Parameswaran Nair
wiley   +1 more source

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Profiles of a Single‐Dose JYB1904 in Healthy Chinese Participants: A Phase Ia, Randomized, Double‐Blind, Placebo‐Controlled Study

Clinical and Translational Science, Volume 18, Issue 6, June 2025.
ABSTRACT Allergic asthma, characterized by airborne allergen sensitivity and Th2 immune responses, is a common and increasing global health concern. Omalizumab, while effective, has limitations such as weight‐ and IgE‐dependent dosing regimens. JYB1904, a recombinant anti‐IgE humanized monoclonal antibody (IgG1 subtype), showed superior preclinical ...
Zhen‐Wei Shen, Ting‐Han Jin, Kai‐Qi Wu, Jie Zhao, Qi Jiang, Tong Guo, Liang Li, Xiao‐Hua Feng, Pei‐pei Liu, Gui‐Ling Chen   +9 more
wiley   +1 more source